NeuroPace (NPCE) Q3 2024 earnings summary

Executive summary

• Achieved record Q3 2024 revenue of $21.1 million, up 28% year-over-year, driven by RNS System and DIXI Medical product sales, with Project CARE and community expansion initiatives contributing to growth.

• Gross margin remained strong at 73.2%, within the 72%-74% target range, and net loss narrowed to $5.5 million from $7.3 million in Q3 2023.

• Cash and short-term investments totaled $56.8 million as of September 30, 2024, supporting operations and growth initiatives through at least 2026.

• Expanded sales force and leadership team, with new heads of marketing, R&D, and HR, to support market development and growth.

• Strategic focus on expanding RNS System access outside Level 4 centers and into new clinical indications, including generalized epilepsy.

Financial highlights

• Q3 2024 revenue: $21.1 million, up 28% year-over-year; nine-month revenue: $58.4 million, up 23% from prior year.

• Gross margin: 73.2% in Q3 2024, within guidance; operating expenses: $19.7 million, up 8% year-over-year.

• Net loss: $5.5 million in Q3 2024 (improved from $7.3 million in Q3 2023); EPS: $(0.19) per share.

• Cash and short-term investments: $56.8 million as of September 30, 2024.

• Long-term borrowings: $59.3 million as of September 30, 2024; debt matures September 2026.

Outlook and guidance

• 2024 revenue guidance raised to $78–$80 million, representing 19%-22% growth over 2023.

• Gross margin expected to remain in 72%-74% range for 2024; operating expenses projected at $80–$84 million, including ~$10 million in stock-based compensation.

• Current cash position expected to fund operations for the foreseeable future, with potential for additional capital if needed.

• Focus on expanding RNS System access and new indications, with continued investment in R&D and commercial activities.